Xeris Biopharma Holdings, Inc.
XERS
$5.70
-$0.015-0.26%
| Weiss Ratings | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.70 | |||
| Price History | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 9.10% | |||
| 30-Day Total Return | 59.08% | |||
| 60-Day Total Return | 66.03% | |||
| 90-Day Total Return | 80.79% | |||
| Year to Date Total Return | 64.60% | |||
| 1-Year Total Return | 179.17% | |||
| 2-Year Total Return | 348.43% | |||
| 3-Year Total Return | 111.71% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -5.93% | |||
| 52-Week Low % Change | 237.87% | |||
| Price | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $6.07 | |||
| 52-Week Low Price | $1.69 | |||
| 52-Week Low Price (Date) | Apr 19, 2024 | |||
| 52-Week High Price (Date) | Mar 26, 2025 | |||
| Valuation | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 879.00M | |||
| Enterprise Value | 1.08B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.38 | |||
| Earnings Per Share Growth | -16.87% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 4.19 | |||
| Price/Book (Q) | -28.81 | |||
| Enterprise Value/Revenue (TTM) | 5.31 | |||
| Price | $5.70 | |||
| Enterprise Value/EBITDA (TTM) | -69.71 | |||
| Enterprise Value/EBIT | -39.16 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 149.09M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 844 445 5704 | |||
| Address | 1375 West Fulton Street Chicago, IL 60607 | |||
| Website | www.xerispharma.com | |||
| Country | United States | |||
| Year Founded | 2005 | |||
| Profitability | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -13.56% | |||
| Profit Margin | -27.00% | |||
| Management Effectiveness | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -5.33% | |||
| Return on Equity | -- | |||
| Income Statement | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 203.07M | |||
| Total Revenue (TTM) | 203.07M | |||
| Revenue Per Share | $1.36 | |||
| Gross Profit (TTM) | 166.24M | |||
| EBITDA (TTM) | -15.48M | |||
| EBIT (TTM) | -27.55M | |||
| Net Income (TTM) | -54.84M | |||
| Net Income Avl. to Common (TTM) | -54.84M | |||
| Total Revenue Growth (Q YOY) | 35.39% | |||
| Earnings Growth (Q YOY) | 61.81% | |||
| EPS Diluted (TTM) | -0.38 | |||
| EPS Diluted Growth (Q YOY) | 64.60% | |||
| Balance Sheet | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 71.62M | |||
| Cash Per Share (Q) | $0.48 | |||
| Total Current Assets (Q) | 167.66M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -29.62M | |||
| Current Ratio (Q) | 1.669 | |||
| Book Value Per Share (Q) | -$0.20 | |||
| Total Assets (Q) | 323.06M | |||
| Total Current Liabilities (Q) | 100.44M | |||
| Total Debt (Q) | 271.45M | |||
| Total Liabilities (Q) | 352.68M | |||
| Total Common Equity (Q) | -29.62M | |||
| Cash Flow | XERS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 4.88M | |||
| Cash from Financing (TTM) | 36.17M | |||
| Net Change in Cash (TTM) | 4.07M | |||
| Levered Free Cash Flow (TTM) | -27.81M | |||
| Cash from Operations (TTM) | -36.98M | |||
